NASDAQ:EDAP - Edap Tms Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.75
  • Forecasted Upside: 40.59 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.09
▼ -0.08 (-1.92%)
1 month | 3 months | 12 months
Get New Edap Tms Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDAP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDAP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.75
▲ +40.59% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Edap Tms in the last 3 months. The average price target is $5.75, with a high forecast of $6.00 and a low forecast of $5.50. The average price target represents a 40.59% upside from the last price of $4.09.
Buy
The current consensus among 2 investment analysts is to buy stock in Edap Tms. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020HC WainwrightBoost Price TargetBuy$5.00 ➝ $6.00Low
i
4/15/2020B. RileyInitiated CoverageBuy$5.50Medium
i
Rating by A. D'silva at B. Riley
4/1/2020HC WainwrightLower Price TargetBuy$6.50 ➝ $5.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/15/2019HC WainwrightReiterated RatingBuy$6.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/30/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/11/2019HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/17/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/3/2019HC WainwrightReiterated RatingBuy$6.50Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/16/2018HC WainwrightReiterated RatingBuy$7.00High
i
Rating by S. Ramakanth at HC Wainwright
9/4/2018HC WainwrightReiterated RatingBuyLow
i
Rating by S. Ramakanth at HC Wainwright
7/2/2018HC WainwrightReiterated RatingBuy$6.50Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/16/2018HC WainwrightReiterated RatingBuy$6.50Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/29/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/22/2017HC WainwrightReiterated RatingBuy$6.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/9/2017HC WainwrightReiterated RatingBuy$6.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/25/2017HC WainwrightReiterated RatingBuy$6.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/19/2017HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/22/2017HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/7/2017HC WainwrightReiterated RatingBuy$7.00Low
i
8/30/2016HC WainwrightReiterated RatingBuyN/A
i
(Data available from 11/23/2015 forward)
Edap Tms logo
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.
Read More

Today's Range

Now: $4.09
$4.01
$4.25

50 Day Range

MA: $4.46
$4.13
$4.93

52 Week Range

Now: $4.09
$1.46
$5.39

Volume

80,691 shs

Average Volume

106,460 shs

Market Capitalization

$118.60 million

P/E Ratio

409.41

Dividend Yield

N/A

Beta

2.15